Perth biotech company PYC Therapeutics has hit a major milestone in the development of a first-in-class drug to treat a rare eye disease, recently receiving orphan drug designation from the US FDA.

Perth biotech company PYC Therapeutics has hit a major milestone in the development of a first-in-class drug to treat a rare eye disease, recently receiving orphan drug designation from the US FDA.